Top Midday Gainers

MT Newswires Live

Yesterday

Q32 Bio's (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics (AKBA).

More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.

Kala Bio (KALA) said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.

Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.

Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.

Belite Bio (BLTE) said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.

Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.

Price: 4.40, Change: +2.21, Percent Change: +100.91

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2588377769"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588377769\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588377769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 02:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588377769","market":"fut","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/QTTB\">Q32 Bio</a>'s (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA).</p><p>More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.</p><p><a href=\"https://laohu8.com/S/KALA\">Kala Bio</a> (KALA) said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.</p><p>Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.</p><p>Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.</p><p><a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a> (BLTE) said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.</p><p>Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.</p><p>Price: 4.40, Change: +2.21, Percent Change: +100.91</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-02 02:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/QTTB\">Q32 Bio</a>'s (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA).</p><p>More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.</p><p><a href=\"https://laohu8.com/S/KALA\">Kala Bio</a> (KALA) said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.</p><p>Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.</p><p>Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.</p><p><a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a> (BLTE) said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.</p><p>Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.</p><p>Price: 4.40, Change: +2.21, Percent Change: +100.91</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALA","symbol_name":"KALA BIO","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588377769","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588377769","pubTimestamp":1764613968,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Q32 Bio's  shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio  said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio  said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALA":"KALA BIO","BK4007":"制药","QTTB":"Q32 Bio Inc.","AKBA":"Akebia Therapeutics, Inc.","BLTE":"Belite Bio, Inc.","BK4139":"生物科技"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALA":1,"QTTB":1,"AKBA":1,"BLTE":1},"content_text":"Q32 Bio's (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics (AKBA).More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio (KALA) said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio (BLTE) said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +100.91","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}